Chargement des cours...
Prévisions
Aucune donnée d'analyste n'est disponible pour cette entreprise.
Actualités Accéder au fil d'actualités
Medios exceeds half‑year revenue of €1bn for first time, but lowers EBITDA forecast
Medios increased revenue in the first half of 2026 by 8.4% to €1.075bn, reaching a half‑year revenue above €1bn for the first time. Despite the revenue growth, EBITDA pre fell 5.1% to €44m and the EBITDA‑pre margin dropped to 4.1%, prompting the company to cut its profit forecast for 2026. Operating cash flow was halved to €11.2m, partly due to timing effects in tax payments. Medios acquired a 74% stake in Caelo for €9.4m and raised its revenue forecast for 2026, but expects continued margin pressure and savings from the Avanti‑Medios! program. » Plus sur de.investing.com
Medios acquires 74% of Caesar & Loretz and moves into the German active-ingredient market
Medios is buying 74 percent of Caesar & Loretz GmbH (Caelo), based in Hilden; the transaction is expected to close in the fourth quarter of 2026. Caelo is projected to generate around €40 million in revenue in 2026, roughly 2% of Medios’s planned revenue, but primarily serves as a door opener for entry into the market for pharmaceutical active and auxiliary substances. Medios is likely to consider further internal or external measures to strengthen this area; Q2 figures will be published tomorrow after the profit target for 2026 was already lowered. » Plus sur finanzen.net
Medios acquires 74 percent of Caelo and confirms annual forecast
Medios purchases 74 percent of Caesar & Loretz (Caelo); the credit‑financed purchase price is in the upper single‑digit millions and depends on future performance. Caelo expects revenue of around €40 million for 2026 and will be fully consolidated after closing. Completion is subject to market‑standard conditions and is expected in Q4 2026; the takeover has no impact on the annual forecast. Investor reaction: Medios share initially rose by about 1 percent. » Plus sur finanzen.net
Dividendes historiques Dividendes
Tous les indicateurs de dividendes Tous les indicateursDonnées financières de l'entreprise
| (EUR) | juin 2026 | |
|---|---|---|
| Chiffre d'affaires | 547,31M | 7,94% |
| Bénéfice brut | 20,11M | 12,51% |
| Bénéfice net | 3,54M | 43,75% |
| EBITDA | 19,46M | 5,39% |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 270,31M€ |
Nombre d'actions | 24,80M |
Plus haut/bas sur 52 semaines | 20,60€ - 10,90€ |
| Dividendes | Non |
Bêta | 1,32 |
Ratio P/E | 24,77 |
Ratio PEG | −0,61 |
Ratio P/B | 0,51 |
Ratio P/S | 0,13 |
Profil de l'entreprise
Die Medios AG ist zusammen mit ihren Tochtergesellschaften im Großhandel mit Spezialarzneimitteln in Deutschland tätig. Das Unternehmen ist in den Segmenten Pharmazeutische Versorgung und Patientenspezifische Therapien tätig. Das Segment Pharmazeutische Versorgung bietet Produkte für die Bereiche Onkologie, Neurologie, Autoimmunologie, Augenheilkunde, Infektiologie und Hämophilie an. Das Segment Patientenspezifische Therapien stellt Medikamente für Patienten im Auftrag von Apotheken her und bietet patientenindividuelle Therapien zur Abgabe von individuell dosierten Tabletten an. Das Unternehmen wurde 2016 gegründet und hat seinen Sitz in Berlin, Deutschland.
| Nom | Medios |
| PDG | Thomas Meier |
| Siège social | Berlin,
be Allemagne |
| Site web | |
| Secteur | Santé |
| Industrie | Produits pharmaceutiques |
| Introduction en bourse | 28/12/2007 |
| Employés | 982 |
Deep Dive
Symboles boursiers
| Bourse | Symbole |
|---|---|
London Stock Exchange | 0QB4.L |
XETRA | ILM1.DE |
Pnk | MEDOF |
Frankfurt | ILM1.F |
Düsseldorf | ILM1.DU |
Hamburg | ILM1.HM |
London | 0QB4.L |
SIX | ILM1.SW |
München | ILM1.MU |
Découvrir des actifs
Les actionnaires de Medios investissent également dans les actifs suivants